Rabeprazole→see proton pump inhibitors
Rabies vaccine
▶Antimalarials(chloroquine)decrease the efficacy ofrabies
vaccine. Avoid.oStudy
▶Hydroxychloroquineis predicted to decrease efficacyrabies
vaccine.oTheoretical
Raloxifene→seeTABLE 5p. 847 (thromboembolism)
Raltegravir
▶Antacidsslightly decrease the exposure toraltegravir. Avoid.
oStudy
▶Antiepileptics(carbamazepine)are predicted to affect the
exposure toraltegravir.oTheoretical
▶Antiepileptics(fosphenytoin, phenobarbital, phenytoin,
primidone)are predicted to affect the exposure toraltegravir.
Use with caution or avoid.oTheoretical
▶Calcium salts(calcium carbonate)greatly decrease the exposure
toraltegravir(high-dose). Avoid.rStudy
▶HIV-protease inhibitors(atazanavir)increase the exposure to
raltegravir(high-dose). Avoid.oStudy
▶HIV-protease inhibitors(darunavir)increase the risk of rash
when given withraltegravir.oStudy
▶HIV-protease inhibitors(fosamprenavir)(boosted with ritonavir)
decrease the exposure toraltegravirandraltegravirdecreases
the exposure toHIV-protease inhibitors(fosamprenavir)
(boosted with ritonavir). Avoid.rStudy
▶HIV-protease inhibitors(tipranavir)(boosted with ritonavir) are
predicted to decrease the exposure toraltegravir(high-dose).
Avoid.oStudy
▶Rifampicinslightly decreases the exposure toraltegravir.
Avoid or adjust dose—consult product literature.o
Study
Raltitrexed→seeTABLE 15p. 850 (myelosuppression)
▶Folatesare predicted to alter the effects ofraltitrexed. Avoid.
oStudy
▶Live vaccinesare predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
raltitrexed. Public Health England advises avoid (refer to
Green Book).rTheoretical
Ramipril→see ACE inhibitors
Ramucirumab→see monoclonal antibodies
Ranibizumab
▶Ranibizumabis predicted to increase the risk of bleeding
events when given withargatroban.rTheoretical
▶Ranibizumabis predicted to increase the risk of bleeding
events when given withbivalirudin.oTheoretical
▶Ranibizumabincreases the risk of bleeding events when given
withcoumarins.rTheoretical
▶Ranibizumabis predicted to increase the risk of bleeding
events when given withdanaparoid.rTheoretical
▶Ranibizumabincreases the risk of bleeding events when given
withheparin (unfractionated).rTheoretical
▶Ranibizumabincreases the risk of bleeding events when given
withlow molecular-weight heparins.rTheoretical
▶Ranibizumabis predicted to increase the risk of bleeding
events when given withphenindione.rTheoretical
Ranitidine→see H 2 receptor antagonists
Ranolazine→seeTABLE 9p. 849 (QT-interval prolongation)
▶Ranolazineis predicted to increase the exposure toafatinib.
Separate administration by 12 hours.oStudy
▶Ranolazineis predicted to increase the exposure toaliskiren.
oTheoretical
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure toranolazine.rStudy→Also seeTABLE 9p. 849
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
toranolazine. Avoid.rStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure toranolazine.r
Study→Also seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure toranolazine. Avoid.
rStudy→Also seeTABLE 9p. 849
▶Aprepitantis predicted to increase the exposure toranolazine.
rStudy
▶Ranolazineis predicted to increase the exposure tobeta
blockers, non-selective(nadolol).oStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toranolazine.rStudy
▶Ranolazineis predicted to increase the exposure toceritinib.
oTheoretical→Also seeTABLE 9p. 849
▶Ciclosporinis predicted to increase the concentration of
ranolazineandranolazineis predicted to increase the
concentration ofciclosporin.oTheoretical
▶Cobicistatis predicted to increase the exposure toranolazine.
Avoid.rStudy
▶Ranolazineis predicted to increase the exposure tocolchicine.
Avoid or adjustcolchicinedose.rTheoretical
▶Crizotinibis predicted to increase the exposure toranolazine.
rStudy→Also seeTABLE 9p. 849
▶Ranolazineis predicted to increase the exposure todabigatran.
rTheoretical
▶Ranolazineincreases the concentration ofdigoxin.o
Study
▶Ranolazineis predicted to slightly increase the exposure to
edoxaban.rTheoretical
▶Enzalutamideis predicted to decrease the exposure to
ranolazine. Avoid.rStudy
▶Ranolazineis predicted to increase the exposure toerlotinib.
oTheoretical
▶Ranolazineis predicted to increase the exposure to
fidaxomicin. Avoid.oStudy
▶Grapefruit juiceis predicted to increase the concentration of
ranolazine. Avoid.rTheoretical
▶HIV-protease inhibitorsare predicted to increase the exposure
toranolazine. Avoid.rStudy→Also seeTABLE 9p. 849
▶Idelalisibis predicted to increase the exposure toranolazine.
Avoid.rStudy
▶Imatinibis predicted to increase the exposure toranolazine.
rStudy
▶Ranolazineis predicted to increase the exposure tolomitapide.
Separate administration by 12 hours.oTheoretical
▶Macrolides(clarithromycin)are predicted to increase the
exposure toranolazine. Avoid.rStudy→Also seeTABLE 9
p. 849
▶Macrolides(erythromycin)are predicted to increase the
exposure toranolazine.rStudy→Also seeTABLE 9p. 849
▶Mitotaneis predicted to decrease the exposure toranolazine.
Avoid.rStudy
▶Netupitantis predicted to increase the exposure toranolazine.
rStudy
▶Nilotinibis predicted to increase the exposure toranolazine.
rStudy→Also seeTABLE 9p. 849
▶Ranolazineis predicted to increase the exposure tonintedanib.
oStudy
▶Ranolazineis predicted to increase the exposure to
panobinostat. Adjust dose.oTheoretical→Also see
TABLE 9p. 849
▶Rifampicinis predicted to decrease the exposure toranolazine.
Avoid.rStudy
▶St John’sWortis predicted to decrease the exposure to
ranolazine. Avoid.rStudy
▶Ranolazineis predicted to increase the exposure tostatins
(atorvastatin).oTheoretical
▶Ranolazineslightly increases the exposure tostatins
(simvastatin). Adjustsimvastatindose,p. 134.oStudy
▶Ranolazineincreases the concentration oftacrolimus. Adjust
dose.rAnecdotal
▶Ranolazineis predicted to increase the exposure toticagrelor.
Use with caution or avoid.rStudy
▶Ranolazineis predicted to increase the exposure totopotecan.
rStudy
▶Ranolazineis predicted to increase the concentration of
trametinib.oTheoretical
▶Ranolazineis predicted to increase the exposure tovenetoclax.
Avoid or monitor for toxicity.rTheoretical
Rasagiline→see monoamine-oxidase B inhibitorsBNFC 2018 – 2019 Rabeprazole—Rasagiline 979
Interactions|Appendix 1A1